News

17/11/2003 - Successful photodynamic therapy for nonresectable cholangiocarcinoma.

In nonrandomized trials, photodynamic therapy (PDT) had a promising effect on nonresectable cholangiocarcinoma (NCC). A new prospective, open-label, randomized, multicenter study with a group sequential design compared PDT in addition to stenting (group A) with stenting alone (group B) in patients with NCC. PDT resulted in prolongation of survival (group A: n = 20, median 493 days; group B: n = 19, median 98 days; P < 0.0001). It also improved biliary drainage and quality of life. The results led the Authors to conclude that PDT, given in addition to best supportive care, improves survival in patients with NCC. The study was even terminated prematurely because PDT proved to be so superior to simple stenting treatment that further randomization was deemed unethical. Reach the paper through: Gastroenterology 125(5):1355-1363, November 2003.

News Archive

3/8/2001	WHY?
17/11/2001	W.H.O. Collaborating Centre for Cancer Control of Uncommon Tumours
10/12/2001	On November 30th, in the hall of the S. Pio X Private Hospital of Milan, Italy, the "Rare Tumor: actuality and projects" congress took place.
18/12/2001	Post-meeting survey
3/12/2002	QUIZ
5/5/2002	Dear Colleagues,
29/01/2003	New publication on rare cancers !
28/07/2003	Thyroid Cancer Treatment Receives Orphan Drug Status
02/08/2003	Breast cancer in men
24/09/2003	GISTs: The revolution continues
28/10/2003	Lessons learned from the management of a rare genetic cancer.
07/01/2004	Gene associated with higher risk of melanoma in men
08/03/2004	Susceptibility to Common Adult Cancers in Retinoblastoma Survivors
29/03/2004	FDA Approves First Drug for mesothelioma
25/08/2004	Gene therapy cures malignant melanoma in mice
20/10/2004	FDA grants orphan drug status to two new anticancer drugs.
15/11/2004	New experimental drug for myeloproliferative disorder
20/01/2005	New leukemia treatment granted FDA orphan drug status.
28/02/2005	U.S. F.D.A. grants new orphan drug designation for a targeted therapeutic for head and neck cancer.
02/05/2005	Possible targets for a multiple myeloma vaccine
17/10/2005	Orphan drug troxacitabine approved for AML in EU
03/11/2005	FDA designes interleukin 21 as an orphan drug
01/12/2005	Zactima has received FDA orphan drug designation
25/01/2006	CETT Program for Rare Genetic Diseases
23/02/2006	New research studies of multiple myeloma